CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy

被引：47
|
作者：
Murad, Yanal M.
Clay, Timothy M.
Lyerly, H. Kim
Morse, Michael A.
机构：
[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Program Mol Therapeut, Duke Comprehens Canc Ctr,Dept Pathol & Immunol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Program Mol Therapeut, Comprehens Canc Ctr,Dept Med, Durham, NC 27710 USA
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期
关键词：
adjuvant; CPG-7909; PF-3512676; ProMune; TLR9;
D O I：
10.1517/14712598.7.8.1257
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.
引用
收藏
页码：1257 / 1266
页数：10
相关论文
共 50 条
  • [41] Toll-like receptor 9 mediates CpG-DNA signaling
    Chuang, TH
    Lee, J
    Kline, L
    Mathison, JC
    Ulevitch, RJ
    JOURNAL OF LEUKOCYTE BIOLOGY, 2002, 71 (03) : 538 - 544
  • [42] Direct binding of Toll-like receptor 9 to CpG-DNA
    不详
    IMMUNOBIOLOGY, 2004, 209 (4-6) : 324 - 324
  • [43] Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides
    Krieg A.M.
    Current Oncology Reports, 2004, 6 (2) : 88 - 95
  • [44] Mitochondrial DNA and Toll-Like Receptor-9 Are Associated With Mortality in Critically Ill Patients
    Krychtiuk, Konstantin A.
    Ruhittel, Sarah
    Hohensinner, Philipp J.
    Koller, Lorenz
    Kaun, Christoph
    Lenz, Max
    Bauer, Benedikt
    Wutzlhofer, Lisa
    Draxler, Dominik F.
    Maurer, Gerald
    Huber, Kurt
    Wojta, Johann
    Heinz, Gottfried
    Niessner, Alexander
    Speidl, Walter S.
    CRITICAL CARE MEDICINE, 2015, 43 (12) : 2633 - 2641
  • [45] Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms
    Berenson, Charles S.
    Kruzel, Ragina L.
    Wrona, Catherine T.
    Mammen, Manoj J.
    Sethi, Sanjay
    PLOS ONE, 2015, 10 (09):
  • [46] Toll-like receptor-9 activation ameliorates hepatic fibrosis associated with lymphocyte interactions
    Axelrod, Jonathan H.
    Khvalevsky, Elena
    Doron, Sarit
    Enk, Jonathan
    Nechemia, Yael
    Pappo, Orit
    Galun, Eithan
    Safadi, Rifaat
    HEPATOLOGY, 2007, 46 (04) : 706A - 706A
  • [47] Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro
    Sandholm, Jouko
    Tuomela, Johanna
    Kauppila, Joonas H.
    Harris, Kevin W.
    Graves, David
    Selander, Katri S.
    ONCOLOGY LETTERS, 2014, 8 (01) : 266 - 274
  • [48] A critical role of CpG motifs in a murine peritonitis model by their binding to highly expressed toll-like receptor-9 on liver NKT cells
    Tsujimoto, Hironori
    Ono, Satoshi
    Matsumoto, Atsushi
    Kawabata, Toshinobu
    Kinoshita, Manabu
    Majima, Takashi
    Hiraki, Shuichi
    Seki, Shuhji
    Moldawer, Lyle L.
    Mochizuki, Hidetaka
    JOURNAL OF HEPATOLOGY, 2006, 45 (06) : 836 - 843
  • [49] Toll-like receptor agonists in cancer therapy
    Adams, Sylvia
    IMMUNOTHERAPY, 2009, 1 (06) : 949 - 964
  • [50] Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)
    Iliev, AI
    Stringaris, AK
    Nau, R
    Neumann, H
    FASEB JOURNAL, 2003, 17 (15): : 412 - +
12345